You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for New Drug Application (NDA): 212154


✉ Email this page to a colleague

« Back to Dashboard


NDA 212154 describes VILTEPSO, which is a drug marketed by Nippon Shinyaku and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the VILTEPSO profile page.

The generic ingredient in VILTEPSO is viltolarsen. One supplier is listed for this compound. Additional details are available on the viltolarsen profile page.
Summary for 212154
Tradename:VILTEPSO
Applicant:Nippon Shinyaku
Ingredient:viltolarsen
Patents:2
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 212154
Generic Entry Date for 212154*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 212154
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VILTEPSO viltolarsen SOLUTION;INTRAVENOUS 212154 NDA NS Pharma, Inc. 73292-011 73292-011-01 1 VIAL, GLASS in 1 CARTON (73292-011-01) / 1 INJECTION, SOLUTION in 1 VIAL, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength250MG/5ML (50MG/ML)
Approval Date:Aug 12, 2020TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 12, 2027
Regulatory Exclusivity Use:INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
Regulatory Exclusivity Expiration:Aug 12, 2025
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:10,870,676Patent Expiration:Aug 31, 2031Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.